These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

279 related items for PubMed ID: 15788682

  • 1. A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin.
    Ma PC, Schaefer E, Christensen JG, Salgia R.
    Clin Cancer Res; 2005 Mar 15; 11(6):2312-9. PubMed ID: 15788682
    [Abstract] [Full Text] [Related]

  • 2. Small molecule c-MET inhibitor PHA665752: effect on cell growth and motility in papillary thyroid carcinoma.
    Chattopadhyay C, El-Naggar AK, Williams MD, Clayman GL.
    Head Neck; 2008 Aug 15; 30(8):991-1000. PubMed ID: 18327775
    [Abstract] [Full Text] [Related]

  • 3. A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts.
    Puri N, Khramtsov A, Ahmed S, Nallasura V, Hetzel JT, Jagadeeswaran R, Karczmar G, Salgia R.
    Cancer Res; 2007 Apr 15; 67(8):3529-34. PubMed ID: 17440059
    [Abstract] [Full Text] [Related]

  • 4. A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase.
    Sattler M, Pride YB, Ma P, Gramlich JL, Chu SC, Quinnan LA, Shirazian S, Liang C, Podar K, Christensen JG, Salgia R.
    Cancer Res; 2003 Sep 01; 63(17):5462-9. PubMed ID: 14500382
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.
    Amornphimoltham P, Patel V, Sodhi A, Nikitakis NG, Sauk JJ, Sausville EA, Molinolo AA, Gutkind JS.
    Cancer Res; 2005 Nov 01; 65(21):9953-61. PubMed ID: 16267020
    [Abstract] [Full Text] [Related]

  • 7. Involvement of the Akt/mTOR pathway on EGF-induced cell transformation.
    Nomura M, He Z, Koyama I, Ma WY, Miyamoto K, Dong Z.
    Mol Carcinog; 2003 Sep 01; 38(1):25-32. PubMed ID: 12949840
    [Abstract] [Full Text] [Related]

  • 8. Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma in situ.
    Namba R, Young LJ, Abbey CK, Kim L, Damonte P, Borowsky AD, Qi J, Tepper CG, MacLeod CL, Cardiff RD, Gregg JP.
    Clin Cancer Res; 2006 Apr 15; 12(8):2613-21. PubMed ID: 16638874
    [Abstract] [Full Text] [Related]

  • 9. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
    Nakachi I, Naoki K, Soejima K, Kawada I, Watanabe H, Yasuda H, Nakayama S, Yoda S, Satomi R, Ikemura S, Terai H, Sato T, Ishizaka A.
    Mol Cancer Res; 2010 Aug 15; 8(8):1142-51. PubMed ID: 20647329
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of the met receptor in mesothelioma.
    Mukohara T, Civiello G, Davis IJ, Taffaro ML, Christensen J, Fisher DE, Johnson BE, Jänne PA.
    Clin Cancer Res; 2005 Nov 15; 11(22):8122-30. PubMed ID: 16299245
    [Abstract] [Full Text] [Related]

  • 11. Effects of CAY10404 on the PKB/Akt and MAPK pathway and apoptosis in non-small cell lung cancer cells.
    Cho Y, Park MJ, Park M, Min SS, Yee J, Kim C, Han MS, Han SH.
    Respirology; 2009 Aug 15; 14(6):850-8. PubMed ID: 19703066
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
    Qian F, Engst S, Yamaguchi K, Yu P, Won KA, Mock L, Lou T, Tan J, Li C, Tam D, Lougheed J, Yakes FM, Bentzien F, Xu W, Zaks T, Wooster R, Greshock J, Joly AH.
    Cancer Res; 2009 Oct 15; 69(20):8009-16. PubMed ID: 19808973
    [Abstract] [Full Text] [Related]

  • 13. Phosphorylation of ribosomal p70 S6 kinase and rapamycin sensitivity in human colorectal cancer.
    Nozawa H, Watanabe T, Nagawa H.
    Cancer Lett; 2007 Jun 18; 251(1):105-13. PubMed ID: 17175097
    [Abstract] [Full Text] [Related]

  • 14. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers.
    Li YY, Chang JW, Chou WC, Liaw CC, Wang HM, Huang JS, Wang CH, Yeh KY.
    Lung Cancer; 2008 Feb 18; 59(2):180-91. PubMed ID: 17900752
    [Abstract] [Full Text] [Related]

  • 15. Phosphatidylinositol-3 kinase/Akt/p70S6K/AP-1 signaling pathway mediated benzo(a)pyrene-induced cell cycle alternation via cell cycle regulatory proteins in human embryo lung fibroblasts.
    Gao A, Liu B, Shi X, Jia X, Ye M, Jiao S, You B, Huang C.
    Toxicol Lett; 2007 Apr 05; 170(1):30-41. PubMed ID: 17383120
    [Abstract] [Full Text] [Related]

  • 16. An in vivo model of Met-driven lymphoma as a tool to explore the therapeutic potential of Met inhibitors.
    Accornero P, Lattanzio G, Mangano T, Chiarle R, Taulli R, Bersani F, Forni PE, Miretti S, Scuoppo C, Dastrù W, Christensen JG, Crepaldi T, Ponzetto C.
    Clin Cancer Res; 2008 Apr 01; 14(7):2220-6. PubMed ID: 18381964
    [Abstract] [Full Text] [Related]

  • 17. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.
    Maulik G, Kijima T, Ma PC, Ghosh SK, Lin J, Shapiro GI, Schaefer E, Tibaldi E, Johnson BE, Salgia R.
    Clin Cancer Res; 2002 Feb 01; 8(2):620-7. PubMed ID: 11839685
    [Abstract] [Full Text] [Related]

  • 18. Molecular predictors of sensitivity to the MET inhibitor PHA665752 in lung carcinoma cells.
    Matsubara D, Ishikawa S, Oguni S, Aburatani H, Fukayama M, Niki T.
    J Thorac Oncol; 2010 Sep 01; 5(9):1317-24. PubMed ID: 20736805
    [Abstract] [Full Text] [Related]

  • 19. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.
    Gorshtein A, Rubinfeld H, Kendler E, Theodoropoulou M, Cerovac V, Stalla GK, Cohen ZR, Hadani M, Shimon I.
    Endocr Relat Cancer; 2009 Sep 01; 16(3):1017-27. PubMed ID: 19509067
    [Abstract] [Full Text] [Related]

  • 20. K252a inhibits the oncogenic properties of Met, the HGF receptor.
    Morotti A, Mila S, Accornero P, Tagliabue E, Ponzetto C.
    Oncogene; 2002 Jul 25; 21(32):4885-93. PubMed ID: 12118367
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.